Anavex Life Sciences Corp (AVXL)

[falconer66a]

Clinical results are required.

falconer, do you want to put together a 100 word blurb for release [for re-posting on other message boards, informing readers of how Anavex will change things]?

Thanks for the invitation. Indeed, it’s time for the Anavex story to be presented and read by the same large, public audiences that have learned of Aduhelm. That flawed new drug was to give hope for those suffering from Alzheimer’s, but as things are turning out, it will be worthless (even at a cost of $56,000 or so a year).

The challenge to convey the essence of the Anavex story in a hundred words seems impossible. Before this paragraph there are 91 words. I’m afraid that real articles, not just a paragraph or two, will be required to open and enlighten the minds of the general public. Even if all of us were to post in online “comments” addenda our collective utterances on the favorability of Anavex, little would happen.

I’ve contended for some time that public perceptions of Anavex (when there are any) derive almost solely from media postings by writers. Presently, there are few. Most media mentions of Anavex occur as tangential references in articles focused on other drugs. Presently, Anavex is but an incidental afterthought.

Few writers are going to take much interest in anything about Anavex Life Sciences Corp, or blarcamesine. Nothing really to write about (they think). For those on the outside, the only things to look at on the inside are still conjectural, even hypothetical. Sure, the company thinks it has a new drug that can help with several big CNS diseases, by operating in neurons like no other drug. Sure. But where are the data that support such contentions? Healed rats don’t a make a good story.

Now we’ve seen and understand the early clinical results for Rett and Parkinson’s. Profound. But those were early-stage clinical tests; cannot (by those who don’t know the underlying science) be confidently projected out to full drug approval and therapeutic usages. Media writers can neither see what we can (that blarcamesine will be a successful CNS drug), nor that it does have an astounding new, unique mechanism of action. It works, so safely like no other CNS drug. So, few writers are going to step to the edge of accuracy and proclaim any of this.

When the AVATAR clinical results for Rett syndrome appear, they will be profoundly significant; providing symptomatic improvements heretofore unattainable. Great for the girls with this genetic disease. But very few readers of popular media have ever heard of “Rett syndrome.” Pretty obscure stuff; not much to write home (or newspaper articles) about.

Hope I’m wrong; that AVATAR results will, indeed, change public perceptions. Very likely, however, that won’t change until the Parkinson’s disease dementia results appear. Or, those, too, may be disregarded in the public press. Not so, however, when finally the big Alzheimer’s results appear. Then, Anavex will be the new Aduhelm story, but with therapeutic successes (and greatly reduced costs). Front-page stuff.